Cite
HARVARD Citation
Stahler, A. et al. (2022). First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110). European journal of cancer. pp. 194-203. [Online].